Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Short Interest Up 20.6% in December

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 8,683,300 shares, an increase of 20.6% from the November 30th total of 7,201,300 shares. Based on an average daily volume of 1,400 shares, the days-to-cover ratio is presently 6,202.4 days.

Sino Biopharmaceutical Price Performance

SBMFF remained flat at $0.41 during trading on Friday. Sino Biopharmaceutical has a one year low of $0.31 and a one year high of $0.47. The firm has a fifty day moving average price of $0.44 and a two-hundred day moving average price of $0.40.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.